Phage approved in food, why not as a therapeutic?

References

• Hankin M. L’action bactericide des eaux de la Jumna et du Gangesur le vibrion du cholera. Ann Inst Pasteur 1896;10:511-23
   Google Scholar
• Twort F. An investigation on the nature of ultra microscopic viruses. Lancet 1915;186:1241-3
   Google Scholar
• D’Herelle F. Sur un microbe invisible antagoniste des bacillus dysenteriques. ComptesRendus Acad Sci 1917;165:373-5
   Google Scholar
• Monk A, Rees C, Barrow P, et al. Bacteriophage applications: where are we now? Lett Appl Microbiol 2010;51:363-9
   PubMed Web of Science ®Google Scholar
• Endersen L, O’Mahony J, Hill C, et al. Phage Therapy in the Food Industry. Ann Rev food sci. & technol 2014;5:327-49
   PubMed Web of Science ®Google Scholar
• Barr JJ, Auro R, Furlan M, et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci USA 2013;110:10771-6
   PubMed Web of Science ®Google Scholar
• Sulakvelidze A. The challenges of bacteriophage therapy. Eur Ind Pharm 2011;10:14-18
   Google Scholar
• Ryan E, Gorman S, Donnelly R, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J pharm pharmacol 2011;63:1253-64
   PubMed Web of Science ®Google Scholar
• Thiel K. Old dogma, new tricks—21st Century phage therapy. Nature Biotechnol 2004;22:31-6
   PubMed Web of Science ®Google Scholar
• Merabishvili M, De Vos D, Verbeken G, et al. Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany. PLoS One 2012;7:e52709
   Google Scholar
• Leung E, Weil D, Raviglione M, Nakatani EH. The WHO policy package to combat antimicrobial resistance. Bull World Health Organ 2011;89:390-2
   PubMed Web of Science ®Google Scholar
• Brain T. Race against time to develop new antibiotics. Bull World Health Organ 2011;89:88-9
   PubMedGoogle Scholar
• Gravitz L. Turning a new phage. Nature Med 2012;18:1318-20
   PubMed Web of Science ®Google Scholar
• Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-64
   PubMed Web of Science ®Google Scholar
• Pirnay JP, Verbeken G, Rose T, et al. Introducing yesterday’s phage therapy in today’s medicine. Future Virol 2012;7:379-90
   Google Scholar
• Smith H, Huggins M. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets, and lambs. J Gen Microbiol 1983;129:2659-75
   PubMedGoogle Scholar
• Smith H, Huggins M, Shaw K. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. J Gen Microbiol 1987;133:1127-35
   PubMedGoogle Scholar
• Chibani-Chennoufi S, Sidoti J, Bruttin A, et al. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob Agents Chemother 2004;48:2558-69
   PubMed Web of Science ®Google Scholar
• Ahmad S. Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med Hypotheses 2002;58:327-31
   PubMedGoogle Scholar
• Soothill J. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 1992;37:258-61
   PubMed Web of Science ®Google Scholar
• Bogovazova G, Voroshilova N, Bondarenko V. Immuno-biological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zh Mikrobiol Epidemiol Immunobiol 1992;3.30-3
   PubMedGoogle Scholar
• Cerveny K, DePaola A. Duckworth D, Gulig PA. Phage therapy of local and systemic disease caused by Vibrio vulnificusin iron-dextran-treated mice. Infect Immun 2002;70:6251-62
   PubMed Web of Science ®Google Scholar
• Toro H, Price S, McKee A, et al. Use of bacteriophages in combination with competitive exclusion to reduce Salmonella from infected chickens. Avian Dis 2005;49:118-24
   PubMed Web of Science ®Google Scholar
• Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 2002;70:204-10
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Yasuda M, Nishikawa H, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage. J Infect Dis 2003;187:613-24
   PubMed Web of Science ®Google Scholar
• Broxmeyer L, Sosnowska D, Miltner E, et al. Killing of Myco-bacterium avium and Mycobacterium tuberculosis by a Mycobacteriophage Delivered by a Nonvirulent Mycobacterium: a Model for Phage Therapy of Intracellular Bacterial Pathogens. The J Infec. Dis 2002;186:1155-60
   Google Scholar
• Kaplan JB. Antibiotic-induced biofilm formation. Int J Artif Organs 2011;34:737-51
   PubMed Web of Science ®Google Scholar
• Harper DR, Parracho HM, Walker J, et al. Bacteriophages and Biofilms. Antibiotics 2014;3:270-84
   Google Scholar
• Lu T, Collins J. Engineered Bacteriophage Targeting Gene Networks as Adjuvants for Antibiotic Therapy. Proc Natl. Acad Sci 2009;106:4629-34
   Google Scholar
• Comeau AM, Tetart F, Trojet SN, et al. Phage-antibiotic synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2007;2:e799
   PubMed Web of Science ®Google Scholar
• Ryan EM, Alkawareek MY, Donnelly RF, et al. Synergistic phage–antibiotic combinations for the control of Escherichia coli biofilms in vitro. FEMS Immunol. Med Microbiol 2012;65:395-8
   Google Scholar
• El-Shibiny A, Scott A, Timms A, et al. Application of a group II Campylobacter bacteriophages to reduce strains of Campylobacter jejuni and Campylobacter coli colonizing broiler chickens. J Food Prot 2009;72:733-40
   PubMed Web of Science ®Google Scholar
• Bardina C, Spricigo DA, Cortes P, Llagostera M. Significance of the bacteriophage treatment schedule in reducing Salmonella colonization in poultry. Appl Environ Microbiol 2012;78:6600-7
   PubMed Web of Science ®Google Scholar
• Raya RR, Oot RA, Moore-Maley B, et al. Naturally resident and exogenously applied T4-like and T5-like bacteriophages can reduce Escherichia coli O157:H7 levels in sheep guts. Bacteriophage 2011;1:15-24
   PubMedGoogle Scholar
• Mills S, Shanahan F, Stanton C, et al. Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes 2013;4:4-16
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang R, Hongduo B. Phage inactivation of foodborne Shigella on ready-to-eat spiced chicken. Poult Sci 2013;92:211-17
   PubMed Web of Science ®Google Scholar
• Guenther S, Huwyler D, Richard S, Loessner MJ. Virulent bacteriophage for efficient biocontrol of Listeria monocytogenes in ready-to-eat foods. Appl Environ Microbial 2009;75:93-100
   PubMed Web of Science ®Google Scholar
• Guenther S, Herzig O, Fieseler L, et al. Biocontrol of Salmonella typhimurium in RTE foods with the virulent bacteriophage FO1-E2. Int J Microbiol 2012;154:66-72
   PubMed Web of Science ®Google Scholar
• Kim KP, Klumpp J, Loessner MJ. Enterobacter sakazakii bacteriophages can prevent bacterial growth in reconstituted infant formula. Int J Food Microbiol 2007;11:195-203
   Google Scholar
• Anany H, Chen W, Pelton R, Griffiths MW. Biocontrol of Listeria monocytogenes and Escherichia coli O157:H7 in meat by using phages immobilized on modified cellulose membranes. Appl Environ.Microbiol 2011;77:6379-87
   PubMed Web of Science ®Google Scholar
• Leverentz B, Conway WS, Camp MJ, et al. Biocontrol of Listeria monocytogenes on fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin. Appl Environ Microbiol 2011;69:4519-26
   Google Scholar
• Viazis S, Akhtar M, Feirtag J, Diez-Gonzalez F. Reduction of Escherichia coli O157:H7 viability on leafy green vegetables by treatment with a bacteriophage mixture and trans-cinnamaldehyde. Food Microbiol 2010;28:149-57
   PubMedGoogle Scholar
• Boyacioglu O, Sharma M, Sulakvelidze A, Goktepe I. Biocontrol of Escherichia coli O157:H7 on fresh cut leafy greens: using a bacteriophage cocktail in combination with modified atmosphere packaging. Bacteriophage 2013;3:e24620
   PubMedGoogle Scholar
• Sulakvelidze A, Alavidze Z, Morris J. Bacteriophage Therapy. Antimicrob Agents And Chemot 2001;45:649-59
   PubMed Web of Science ®Google Scholar
• Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp 1987;35:569-83
   PubMed Web of Science ®Google Scholar
• Abedon ST, Kuhl SJ, Kutter EM. Phage treatment of human infections. Bacteriophage 2011;1:66-85
   PubMedGoogle Scholar
• Goodridge LD, Bisha B. Phage-based biocontrol strategies to reduce foodborne pathogens in foods. Bacteriophage 2011;1:130-7
   PubMed Web of Science ®Google Scholar
• Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 2011;17(1):7-15
   PubMed Web of Science ®Google Scholar
• Razzaghi-Abyaneh M, Shams-Ghahfarokhi M. Natural Antimicrobials in Food Safety and Quality, CABI Publ, Wallingford, UK; 2011
   Google Scholar
• US Environ Prot Agency. Xanthomonas campestris pv. vesicatoria and Pseudomonas syringae pv. tomato specific bacteriophages; exemption from the requirement of a tolerance. Fed Regist 2005.70:16700-4. Available from: www.epa.gov/EPA-PEST/2005/December/Day-28/p24540.pdf [Last accessed on 5 Nov 2014]
   Google Scholar
• Bren L. Bacteria-eating virus approved as food additive. FDA Consum 2007;41:20-2
   PubMedGoogle Scholar
• Garcia P, Rodriguez L, Rodriguez A, Martinez B. Food biopreservation: promising strategies usingbacteriocins, bacteriophages and endolysins. Trends Food Sci Technol 2010;21:373-82
   Web of Science ®Google Scholar
• Parracho H, Burrowes B, Enright M, et al. The role of regulated clinical trials in the development of bacteriophage therapeutics. J mol genet med 2012;6:279-86
   PubMedGoogle Scholar
• Kaur T, Nafissi N, Wasfi O, et al. Immunocompatibility of Bacteriophages as Nanomedicines. J Nanotech 2012;2012:13. Article ID 247427, doi: 10.1155/2012/247427
   Google Scholar
• Nungester W, Watrous R. Accumulation of bacteriophage in spleen and liver following its intravenous inoculation. Proc Soc Exper Biol Med 1934;31:901-5
   Google Scholar
• Inchley C J. The activity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clin Exp Immunol 1969;5:173-87
   PubMedGoogle Scholar
• Merril C, Scholl D, Adhya S. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Dis 2003;2:489-97
   PubMed Web of Science ®Google Scholar
• Lu T, Koeris M. The next generation of bacteriophage therapy. Current Opinion in Microb 2011;14:524-31
   PubMed Web of Science ®Google Scholar
• Merril CR, Biswas B, Carlton R, et al. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci USA 1996;93:3188-92
   PubMed Web of Science ®Google Scholar
• Miedzybrodzki R, Fortuna W, Weber-Dabrowska B, et al. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial virus. Clin Exp Med 2009;9:303-12
   PubMedGoogle Scholar
• Sokoloff A, Bock I, Zhang G, et al. The interactions of peptides with the innate immune system studied with use of T7 phage peptide display. Molec Ther 2000;2:131-9
   PubMed Web of Science ®Google Scholar
• Kim K, Cha J, Jang E, et al. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb Biotechn 2008;1:247-57
   PubMed Web of Science ®Google Scholar
• Molenaar T, Michon I, de Haas S, et al. Uptake and processing of modified bacteriophage M13 in mice: implications for phage display. Virology 2000;293:182-91
   Google Scholar
• Payne R, Jansen V. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacok 2003;42:315-25
   Google Scholar
• Dubos R, Straus J, Pierce C. The multiplication of bacteriophage in vivo and its protective effects against experimental infection with Shigella dysenteria. J Exp Med 1943;20:161-8
   Google Scholar
• Levin B, Bull J. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat 1996;147:881-98
   Web of Science ®Google Scholar
• Sarker S A, McCallin S, Barretto C, et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology 2012;434:222-32
   PubMedGoogle Scholar
• Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents and Chemother 2005;49:2874-8
   PubMed Web of Science ®Google Scholar
• Hagens S, Blasi U. Genetically modified filamentous phage as bactericidal agents: a pilot study. Lett Appl Microbiol 2003;37:318-23
   PubMed Web of Science ®Google Scholar
• Hagens S, Habel A, von Ahsen U, et al. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 2004;48:3817-22
   PubMed Web of Science ®Google Scholar
• Merabishvili M, Pirnay J-P, Verbeken G, et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 2009;4:e4944
   PubMed Web of Science ®Google Scholar
• Hall AR, De Vos D, Friman VP, et al. Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in Wax Moth larvae. Appl Environment Microbiol 2012;78:5646-52
   PubMed Web of Science ®Google Scholar
• Pantucek R, Rosypalova A, Doskar J. The polyvalent staphylococcal phage phi 812: its host-range mutants and related phages. Virology 1998;246:241-52
   PubMedGoogle Scholar
• Carlton R, Noordman W, Biswas B, et al. Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application. Regul Toxicol Pharmacol 2005;43:301-12
   PubMed Web of Science ®Google Scholar
• Marzari R, Sblattero D, Righi M, Bradbury A. Extending filamentous phage host range by the grafting of a heterologous receptor binding domain. Gene 1997;185:27-33
   PubMedGoogle Scholar
• Scholl D, Adhya S, Merril C. Escherichia coli K1’s capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 2005;71:4872-4
   PubMed Web of Science ®Google Scholar
• Moradpour Z, Ghasemian A. Modified phages: novel antimicrobial agents to combat infectious diseases. Biotechnol Adv 2011;29:732-8
   PubMed Web of Science ®Google Scholar
• Loessner M J, Rees CE, Stewart GS. SchererS. Construction of luciferase reporter bacteriophage A511:luxAB for rapid and sensitive detection of viable Listeria cells. Appl environ microbial 1996;62:1133-40
   PubMedGoogle Scholar
• Labrie S, Samson J, Moineau S. Bacteriophage resistance mechanisms. Nature Rev Microb 2010;8:317-27
   PubMed Web of Science ®Google Scholar
• Capparelli R, Nocerino N, Lanzetta R, et al. Bacteriophage-Resistant Staphylococcus aureus Mutant Confers Broad Immunity against Staphylococcal Infection in Mice. PLoS One 2010;5:11720
   PubMed Web of Science ®Google Scholar
• Abuladze T, Li M, Menetrez M, et al. Bacteriophages reduce experimental contamination of hard surfaces, tomato, spinach, broccoli, and ground beef by Escherichia coli O157:H7. Appl Environ Microbiol 2008;74:6230-8
   PubMed Web of Science ®Google Scholar
• Kunisaki H, Tanji Y. Intercrossing of phage genomes in a phage cocktail and stable coexistence with Escherichia coli O157:H7 in anaerobic continuous culture. Appl Microbiol Biotechnol 2010;85:1533-40
   Google Scholar
• Gill J, Hyman P. Phage choice, isolation, and preparation for phage therapy. Curr Pharm Biotechnol 2010;11:2-14
   PubMed Web of Science ®Google Scholar
• Skurnik M, Pajunen M, Kiljunen S. Biotechnological challenges of phage therapy. Biotechnol Lett 2007;29:995-1003
   PubMed Web of Science ®Google Scholar
• Kramberger P, Honour R, Herman R, et al. Purification of the Staphylococcus aureus bacteriophages VDX- 10 on methacrylate monoliths. J Virol Methods 2010;166:60-4
   PubMed Web of Science ®Google Scholar
• Kutter E, De Vos D, Gvasalia G, et al. Phage therapy in clinical practice: treatment of human infection. Curr Pharm Biotechnol 2010;11:69-86
   PubMed Web of Science ®Google Scholar
• Rhoads D, Wolcott R, Kuskowski M, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. J Wound Care 2009;18:237-8
   PubMedGoogle Scholar
• Verbeken G, De Vos D, Vaneechoutte M, et al. European regulatory conundrum of phagetherapy. Future Microbiol 2007;2:485-91
   PubMed Web of Science ®Google Scholar
• WMA Declaration of Helsinki. Ethical principles for medical research involving human subjects. Adopted by the18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the: 59th WMA General Assembly, Seoul, Korea, paragraph 32 October 2008
   Google Scholar
• Heo YJ, Lee YJ, Jung HH, et al. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemoth 2009;53:2469-74
   PubMed Web of Science ®Google Scholar
• Heo Y J, Lee YR, Jung HH, Cho YH. Phage Therapy Against Pseudomonas Aeruginosa. US8282920; 2012
   Google Scholar
• WIPO. Available from: www.wipo.int/portal/en/index.html
   Google Scholar
• Pirnay JP, Verbeken G, Rose T, et al. Introducing yesterday’s phage therapy in today’s medicine. Future Virology 2012;7:379-90
   Google Scholar
• Miedzybrodski B. Phage therapy current Research and Applications. Caister Academic Press 2014
   Google Scholar
• Verbeken G, Pirnay J-P, De Vos D, et al. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch. Immunol Ther Exp 2012;60:161-72
   PubMed Web of Science ®Google Scholar
• Larguinho M, Baptista PV. Gold and silver nanoparticles for clinical diagnostics: from genomics to proteomics. J Proteomics 2012;75:2811-23
   PubMed Web of Science ®Google Scholar
• Dai M, Senecal A, Nugen SR. Electrospun water-soluble polymer nanofibers for the dehydration and storage of sensitive reagents. Nanotechnol 2014;25:225101; 8pp
   PubMed Web of Science ®Google Scholar
• Omnilytics. Available from: www.omnilytics.com/
   Google Scholar
• Exponential Biotherapies. Available from: www.expobio.com/
   Google Scholar
• Biophage Pharma. http:/www.biophagepharma.net/
   Google Scholar
• PhageTech. Available from: www.phagetech.com
   Google Scholar
• Intralytix. Available from: www.mtfalyt(X.com/
   Google Scholar
• Hexal Gentech. Available from: www.hexal gentech.com
   Google Scholar
• Phage Biotech. Available from: www.phagebiotech.com/
   Google Scholar
• GangaGen. Available from: www,gangagen.com/
   Google Scholar
• PhageGen. Available from: www.phagegen.com/
   Google Scholar
• Phico Therapeutics. Available from: www.phicotfierapeutics.co.uk/
   Google Scholar
• Phage-Therapy. Available from: www.phage-1herapy.com/
   Google Scholar
• Ampliphi biosciences. Available from: www.ampliphibio.com/
   Google Scholar
• Novolytics. Available from: www.novolytics.co.uk/
   Google Scholar
• Technophage. Available from: www.technophage.pt
   Google Scholar
• Enzobiotics/New Horizons Diagnostics. Available from: www.nhdiag.com/
   Google Scholar
• Pherecydespharma. Available from: www.pherecydes-pharma.com
   Google Scholar
• ListShield™ Intralytix, Inc. Available from: www.intralytix.com/Intral_Products_ListShield.htm
   Google Scholar
• EcoShield Intralytix, Inc. Available from: www.intralytix.com/Intral_Products_EcoShield.htm
   Google Scholar
• SalmoFresh Intralytix, Inc. Available from: www.intralytix.com/Intral_Products_SalmoFresh.htm
   Google Scholar
• LISTEX™ Micreos EBI Food Safety. Available from: www.micreosfoodsafety.com/en/profile-mission.aspx
   Google Scholar
• Agriphage Omnilytics. Available from: www.omnilytics.com/
   Google Scholar